Notice of Results and R&D day
Source: RNSSilence Therapeutics Notice of Half Year Results and R&D Day
August 15, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce results for the half year ending 30 June 2019, at 7:00am BST on Thursday 12 September 2019.
On 12 September 2019 Silence will also host an R&D Day for investors and analysts at Lotte New York Palace, New York, U.S. Presentations and Q&A will take place from 8:00 a.m. to 12:00 p.m. EST (1:00 p.m. to 5:00 p.m. BST). A live webcast of the presentation can be accessed by visiting 'Results, reports & presentations' in the Investors Section on the Company's website at www.silence-therapeutics.com and an archived replay of the webcast will be available on the Company's website. For further information please contact Brandon.weiner@westwicke.com.
Enquiries:
|
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer
|
Tel: +44 (0)20 3457 6900 |
|
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
|
Tel: +44 (0)20 7418 8900 |
|
European IR Consilium Strategic Communications Mary-Jane Elliott / Chris Welsh/ Angela Gray silencetherapeutics@consilium-comms.com
|
Tel: +44 (0) 20 3709 5700 |
|
US IR Westwicke Partners Peter Vozzo/ Brandon Weiner
|
Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
